| Assessment Status | NCPE assessment ongoing |
| HTA ID | 22001 |
| Drug | Venetoclax |
| Brand | Venclyxto® |
| Indication | In combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 05/01/2022 |
| Rapid review completed | 01/02/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax in combination with a hypomethylating agent compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 23/02/2022 |
| Pre-submission consultation with Applicant | 05/07/2022 |
| Full submission received from Applicant | 13/10/2022 |
